Patents by Inventor Su-Eon Kim

Su-Eon Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230287347
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Application
    Filed: April 4, 2023
    Publication date: September 14, 2023
    Inventors: Tai Gyu KIM, Hyun Jung SOHN, Su Eon KIM
  • CORD BLOOD PLASMA-DERIVED EXOSOME OR MIMETIC THEREOF AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230218678
    Abstract: The present invention relates to a cord blood plasma-derived exosome or a mimetic thereof and a pharmaceutical use thereof. More particularly, the present invention provides the use of a human cord blood plasma-derived exosome or an exosome mimetic that mimics the proteomic profile of the cord blood plasma-derived exosome for the improvement, prevention or treatment of various autoimmune diseases or wound healing.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 13, 2023
    Inventors: Tai Gyu KIM, Su Eon KIM
  • Exosome for stimulating T cell and pharmaceutical use thereof
    Patent number: 11649436
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 16, 2023
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
  • EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOF
    Publication number: 20200071668
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 5, 2020
    Inventors: Tai Gyu KIM, Hyun Jung SOHN, Su Eon KIM
  • Intraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
    Patent number: 6346533
    Abstract: The particle diameter of itraconazole, insoluble drug, is reduced and crystallinity thereof is changed from crystalline into amorphous, increasing water solubility and a dissolution rate thereof. The improved itraconazole is applied to an oral adminstration drug.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: February 12, 2002
    Assignee: Dong-A Pharmaceutical Co., Ltd.
    Inventors: Bong-Jin Cha, Jun-Gyo Oh, Su-Eon Kim